In December 2016, Mercachem and Almirall announced  that Almirall had obtained exclusive rights to Mercachem’s cytokine blockers, and a research collaboration was initiated to optimize these molecules towards candidates for clinical development.

Today, Mercachem is proud to announce the achievement of the first milestone of this research collaboration.

“We are delighted to announce that we have achieved the first milestone within 15 months of collaboration,” said Eelco Ebbers, co-founder and Managing Director of Mercachem. “This shows the innovative research capabilities of Mercachem to progress challenging targets and chemistries, and also demonstrates the true strength of working in partnerships.” 

 

Full Press Release